ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Fujifilm grants Chinese drugmaker patent license on flu drug

TOKYO -- Japan's Fujifilm has inked a patent licensing agreement with China's Zhejiang Hisun Pharmaceutical involving anti-influenza drug Avigan, which has been used to treat Ebola.

The Fujifilm Holdings unit said Wednesday that the Chinese drugmaker may use patents on the effective ingredient of Avigan -- devised by fellow Fujifilm group unit Toyama Chemical -- to develop, produce and market a flu treatment in China. The group is granting the license to another company for the first time.

Unlike most other anti-flu drugs, Avigan blocks viral gene replication in cells to prevent their propagation.

Fujifilm will receive a lump sum as well as royalties when Zhejiang Hisun introduces the product to the market following clinical trials.

Avigan, approved in Japan in 2014 as an anti-flu drug, has been selected as part of the Japanese government's emergency grant aid for fighting Ebola virus disease in Guinea.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends May 26th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media